期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

化疗与靶向药物联合治疗胰腺癌研究进展

Research advancement on chemotherapy combined with target agents in treatment of pancreatic cancer
原文传递
导出
摘要 以吉西他滨为基础的化疗是胰腺癌的主要治疗方法。近年来对于胰腺癌化疗的研究除了吉西他滨与其他化疗药物的联合和给药方法的改进之外，主要集中在化疗与分子靶向药物的联合以及不同靶向药物之间联合应用的探讨。 Gemcitabine is generally accepted as the standard chemotherapeutic agent for advanced pancreatic cancer. Various regimens of gemcitabine and its combination with other chemotherapy drugs are investigated in recent years. Recently the research advances on advanced pancreatic cancer treatment focus not only on the combination of chemotherapy and target agents, but also the combination between different target drugs.
作者 曹阳（综述） 王岩（综述） 徐建明（审校） 宋三泰（审校）
机构地区 军事医学科学院附属医院肿瘤中心
出处 《国际肿瘤学杂志》 CAS 2007年第2期158-160,共3页 Journal of International Oncology
关键词 胰腺肿瘤 治疗 受体 表皮生长因子 受体 血管内皮生长因子 Pancreatic neoplasms Therapy Receptor, epidermal growth factor Receptors, vascular endothelial growth factor
分类号 R730.5 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Di Costanzo F, Carlini P, Doni L, et 81. Gcmcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase Ⅱ trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer,2005,93(2) :185-189.
  • 2Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:results of a GERCOR and GISCAD phase trial. J Clin Onco1,2005,23 ( 15 ) :3509-3516.
  • 3Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase Ⅱ comparison of dose- intense gemeitabine: thirty- minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol,2003,21 ( 18 ) :3402-3408.
  • 4Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol,2003,21(14) :2787-2799.
  • 5Tobita K, Kijima H, Dowaki S,et 81. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med,2003,11(3) :305-309.
  • 6Ng SS,Tsao MS,Nicklee T,et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther,2002,1 (10) :777-783.
  • 7Moore MJ Brief communication, a new combination in the treatment of advanced pancreatic cancer. Semin Oncol,2005,32 ( 6 Suppl 8 ) : 5- 6.
  • 8Bruns C J, Harbison MT, Davis DW, et 81. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res,2000,6 (5) : 1936-1948.
  • 9Xiong HQ, Rosenberg A, LoBaglio A, et al. Cetuximab, a monoelonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase Ⅱ Trial. J Clin Oncol,2004,22(13) :2610-2616.
  • 10Ferram N. Vascular endothelial growth factor:basic science and clinical progress. Endocr Rev,2004,25 (4) :581-611.
国际肿瘤学杂志
2007年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部